In clinical therapy of evolving acute myocardial infarction, coronary reperfusion has proven
to be the only way to limit infarct size, provided it occurs soon enough after coronary artery …

Trimetazidine is a cytoprotective drug whose cardiovascular effectiveness, especially in
patients with stable ischemic heart disease, has been the source of much controversy in …

With evidence for efficacy in such diverse clinical settings such as stable coronary artery
disease, reperfusion injury, and contrast-induced nephropathy, trimetazidine (TMZ) is novel …

The efficacy of trimetazidine, an anti-ischaemic agent, has been largely assessed and
presented in the international literature through its metabolic effects, selective and specific …

Background and objective The aim of this study was to evaluate whether the administration
of trimetazidine, a piperazine derivative, to patients before and after percutaneous coronary …

Background. The aim of the present study was to evaluate potential myocardial protection by
trimetazidine by measurement of the cardiac marker protein troponin T (TnT) during …

Trimetazidine (TMZ) is a widely used drug exerting cardioprotective effects against ischemic
heart disease through a number of mechanisms in conditions of oxidative stress. However …

The objective of this study was to test the hypothesis that the beneficial effect of trimetazidine
during reflow of ischemic hearts is mediated by energy sparing and ATP pool preservation …

This open-label, randomised, controlled study is aimed at assessing the effect of pre-
treatment with the metabolic agent trimetazidine on the degree of ischaemia during …

Acute renal failure (ARF) is often the consequence of an ischemia-reperfusion injury (IRI)
and associated with high mortality. Warm ischemia (WI) is a crucial factor of tissue damage …